Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors - Trial NCT06001684
Access comprehensive clinical trial information for NCT06001684 through Pure Global AI's free database. This Phase 1 trial is sponsored by Imbioray (Hangzhou) Biomedicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Timeline & Enrollment
Phase 1
Sep 01, 2023
Dec 30, 2024
Primary Outcome
Incidence of dose limiting toxicity (DLTs),The incidence and severity of adverse events (AEs)
Summary
This study is an open-label, phase I study to evaluate the safety, tolerability,
 pharmacokinetics (PK), and preliminary efficacy of IBR854 cell injection in patients with
 unresectable, locally advanced, or metastatic solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06001684
Non-Device Trial